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OBJECTIVES: To assess patients’ expectations and experiences
with two treatments for varicose vein disease: duplex-guided
foam sclerotherapy (at the outpatient department) and surgical
stripping (at the daycase centre). These treatments have compa-
rable recurrence rates, but they differ considerably in nature.
Nevertheless, the treatment choice depends on the referral pref-
erence of the general practitioner. METHODS: We conducted
focus groups and in-depth interviews among patients who were
treated for varicose vein disease. We used a semi-structured
script, containing the global structure of the interviews and
probes to be posed to keep the discussion going. Focus groups
and interviews were audiotaped and transcribed. Relevant
topics and differences between expectations and experiences
were extracted. RESULTS: Fourteen patients participated in the
study. Relevant topics in the treatment of varicose vein disease
were health complaints, waiting time, information, treatment
(nature, anaesthesia, location, duration), pain and side-effects,
elastic stockings, usual activities, cosmetic result and retreat-
ment. Information and the elastic stockings were considered as
important. Patients did not like the elastic stockings because
they were aching and warm. Appropriate information was con-
sidered as improving recovery. Differences between expectations
and experiences were seen in anaesthesia and treatment (nature
and duration). Most patients had negative expectations of ana-
esthesia, however, the stripping patients experienced the anaes-
thetic positively. Because of the admission to the daycase centre
and the duration, stripping did feel like real hospitalization.
However, stripping patients had positive experiences. CON-
CLUSIONS: Both treatments were experienced positively. The
general practitioner should discuss the patient’s expectations
and give adequate information to improve outcomes and
satisfaction.
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OBJECTIVES: Planning processes for future diagnostic require-
ments of cardiology departments should be based on sound
clinical and ﬁnancial information. Current diagnosis of CAD is
usually achieved via stress electrocardiography (sECG) / inva-
sive X-Ray coronary angiography (CA). Reliance on these two
techniques alone, however, can result in delays in diagnosis and
subsequent treatment. Imaging techniques such as myocardial
perfusion scintigraphy (MPS), stress echocardiography and
X-ray computed tomography are potentially important modali-
ties and could be incorporated into the diagnostic strategy for
CAD. A model was developed to allow planners and cardiolo-
gists to work together to develop a range of effective diagnostic
strategies; that could help to optimise workload across a range
of diagnostic modalities. METHODS: A 3-module, decision-
support model was developed to simulate diagnosis and man-
agement in a cohort of risk-stratiﬁed patients with suspected
CAD, within a user-deﬁned diagnostic facility. The ‘diagnostic’
module incorporates alternative strategies, comprising combina-
tions of exercise ECG (ExECG), MPS, Stress Echo, multi-slice
computed tomography (MSCT) and coronary angiography
(CA). The ‘treatment’ module is a Markov model incorporating
initial patient management (based upon diagnostic results) and
subsequent patient experience (mortality, future myocardial inf-
arctions (MIs) and revascularisation procedures), according to
severity of disease and therapy at outset. The ‘capacity’ module
deﬁnes the local diagnostic capacity for each modality and com-
pares throughput of the selected strategies for current practice
and an alternative practice format, both of which are user-
deﬁned. RESULTS: Primary outcomes include diagnostic capac-
ity, costs, quality of life and diagnostic accuracy. Including
options of MPS, stress echo and MSCT in the diagnostic strat-
egy for patients considered low or moderate risk reduces the
average cost per 1000 patients by almost £17,000 and increases
the available capacity of CA by 6.7%. CONCLUSIONS: The
use of alternative diagnostic strategies is cost-effective and could
optimise the use of expensive capital equipment.
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OBJECTIVES: In a pharmacoeconomic analysis, price differ-
ences between drugs in a country should be taken into consid-
eration. In addition there are situations where medicines have
the same indication are priced differently. In applying the result
of analysis made overseas to Japan, we should also take into
account not only of different prices from country to country but
also of differences in the pricing method among countries. Thus,
in this study, we compared the differences in drug prices among
selected countries and examined the methodology for an inter-
national comparison of drug prices. METHODS: Using the
ViDAL (France), Rote Liste (Germany) MIMS (UK) and NHI
price list (Japan), we compared the average daily costs at the
time of the introduction of the brand name drugs of antihyper-
tensive agents (ARB, ACE), statins, PPI, and antidepressants
(SSRI, SNRI), in France, Germany, the UK and. Japan We
adopted the WHO-DDD as the average daily dose and converted
the drug prices into euros. We not only compared drug prices
directly but also examined the price range of drugs having the
same efﬁcacy. RESULTS: The drug price differed from country
to country according to the efﬁcacy; while statins and PPI were
most expensive in the U.K., the price of SSRI was the highest in
France. The variation in price of drugs with the same efﬁcacy
was greater in Japan; supposing the price of the cheapest drug in
each therapeutic group to be 1, that of the most expensive drugs
was 3.0 for ARB, 4.1 for statins, 2.5 for PPI and 8.3 for SSRI,
which were on higher levels than those in other countries. CON-
CLUSIONS: Our study suggested that variation in the price of
drugs with the same efﬁcacy might greatly affect pharmacoeco-
nomic analyses.
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